Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial
–News Direct– Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) managing director and CEO James Graham talks with Proactives Jonathan Jackson about how Recce has administered the first doses in the latest cohort…